Trial Profile
Low Dose Thymoglobulin As Induction Agent on Prednisone-Free Regimens of Renal Transplant Recipients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 11 Oct 2013 Planned end date changed from 1 Jan 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 22 May 2013 Results presented at the American Transplant Congress - 13th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.
- 17 Oct 2012 Planned end date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.